PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,771.00
Ask: 1,771.50
Change: -8.50 (-0.48%)
Spread: 0.50 (0.028%)
Open: 1,773.50
High: 1,779.00
Low: 1,764.50
Prev. Close: 1,783.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Britain's FTSE dips on Ukraine nerves; RBS outperforms

Fri, 25th Jul 2014 16:15

* FTSE 100 closes down 0.4 pct after late selloff

* Traders run for exit as Russia accuses Ukraine of selling

* RBS jumps 11 pct as UK upturn boosts results

* BSkyB falls 5.5 pct on news of 4.9 bln pound acquisition

By Francesco Canepa

LONDON, July 25 (Reuters) - Britain's main equity indexclosed lower on Friday as new tensions between Russia andUkraine and falls on Wall Street led traders to cash in on theirweekly gains just before the close.

The FTSE 100 closed 29.91 points, or 0.4 percentlower, at 6,791.55 points, erasing nearly half its weekly gainsin the last hour of trading after Russia accused Ukraine ofhaving shelled across the border.

U.S. indexes also fell, partly weighed down by weak resultsfrom online retailer Amazon and a revenue warning fromthe world's largest credit and debit card company, Visa.

Investors were reluctant to hold on to their long positionsinto the weekend as the geopolitical landscape remainsuncertain.

"There's uncertainty out there in Ukraine and the market hada bit of an exit move," Mark Priest, a senior trader at ETXCapital, said.

BSkyB was the heaviest faller on the FTSE, sliding5.5 percent, after the company placed shares representing nearly10 percent of its capital to finance part of its acquisition ofSky Deutschland and Sky Italia.

Shares in RBS, however, surged 10.8 percent, their biggestrise in four years, after the bank posted a surprise pretaxprofit for the second quarter, citing an economic upturn thatallowed it to write back losses that had been booked on badloans.

Fellow British-focused lenders Barclays and LloydsBanking Group, which are due to report next week, wereup more than 1 percent.

"Credit quality keeps improving, especially in distressedassets such as commercial real estate," said Espirito Santoanalyst Shailesh Raikundlia, who has a "neutral" recommendationon the stock.

"In general, the credit environment is pretty benign andthat should come through in banks' results."

The positive mood on the British economy was underpinned bydata showing economic output in the second quarter finallytopped levels seen before the financial crisis struck six yearsago.

Network operator Vodafone added 4.4 points to theFTSE as it rose 2.1 percent after saying its performance hadbegun to stabilise in several European markets.

Pegging back the index were export-oriented companies suchas heavyweight drugs firm GlaxoSmithKline and fashionbrand Burberry.

GSK knocked 8.9 points off the index as it faced newallegations of corruption, this time in Syria, where thedrugmaker and its distributor have been accused of paying bribesto secure business, according to a whistleblower's email.

Burberry fell 1.6 percent after French luxury goods groupLVMH posted below-forecast second-quarter sales andprofits, hit by a drop in demand from China. (Additional reporting by Lionel Laurent; Editing by SusanFenton)

More News
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.